Brian Druker

Research interests

Publications

• Proteogenomic characterization of pancreatic ductal adenocarcinoma

  Cell · 2021 · https://doi.org/10.1016/j.cell.2021.08.023

• A proteogenomic portrait of lung squamous cell carcinoma

  Cell · 2021 · https://doi.org/10.1016/j.cell.2021.07.016

• Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma

  Cancer Cell · 2021 · https://doi.org/10.1016/j.ccell.2020.12.007

• Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

  Cell · 2020 · https://doi.org/10.1016/j.cell.2020.06.013

• Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1902328

• Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

  Cell · 2019 · https://doi.org/10.1016/j.cell.2019.10.007

• Functional genomic landscape of acute myeloid leukaemia

  Nature · 2018 · 10.1038/s41586-018-0623-z

• Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1609324

• Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1205127

• CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

  Blood · 2010 · 10.1182/blood-2010-03-275305

• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

  Journal of Clinical Investigation · 2010 · 10.1172/jci35721

• Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.25.3724

• AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

  Cancer Cell · 2009 · 10.1016/j.ccr.2009.09.028

• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  Leukemia · 2009 · 10.1038/leu.2009.38

• Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies

  Cancer Research · 2006 · https://doi.org/10.1158/0008-5472.can-05-2050

• Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

  New England Journal of Medicine · 2006 · 10.1056/nejmoa062867

• In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

  Cancer Research · 2005 · 10.1158/0008-5472.can-05-0259

• The development of imatinib as a therapeutic agent for chronic myeloid leukemia

  Blood · 2004 · 10.1182/blood-2004-08-3097

• Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.04.190

• Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

  New England Journal of Medicine · 2003 · 10.1056/nejmoa022457

• Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics

  Annals of Internal Medicine · 2003 · https://doi.org/10.7326/0003-4819-138-10-200305200-00010

• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

  New England Journal of Medicine · 2002 · 10.1056/nejmoa020461

• Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

  New England Journal of Medicine · 2002 · 10.1056/nejmoa011573

• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  Leukemia · 2002 · 10.1038/sj.leu.2402741

• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

  New England Journal of Medicine · 2001 · 10.1056/nejm200104053441402

• Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

  New England Journal of Medicine · 2001 · 10.1056/nejm200104053441401

• Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

  New England Journal of Medicine · 2001 · 10.1056/nejm200104053441404

• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor

  Blood · 2000 · 10.1182/blood.v96.3.925

• Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors

  Journal of Pharmacology and Experimental Therapeutics · 2000 · 10.1016/s0022-3565(24)38879-2

• Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

  Journal of Clinical Investigation · 2000 · 10.1172/jci9083

• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  Nature Medicine · 1996 · 10.1038/nm0596-561

• Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

  PubMed · 1996

Current projects

No projects listed.